Home » Healthcare » Mexico Human Insulin Market

Mexico Human Insulin Market

Mexico Human Insulin Market By Device (Pens, Syringes, Others); By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); By Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Others); By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Mexico Human Insulin Market Size 2023	USD 536.37 million
Mexico Human Insulin Market, CAGR	3.10%
Mexico Human Insulin Market Size 2032	USD 706.76 million

Market Overview

Mexico Human Insulin market size was valued at USD 536.37 million in 2023 and is anticipated to reach USD 706.76 million by 2032, at a CAGR of 3.10% during the forecast period (2023-2032).

The Mexico Human Insulin market is driven by the increasing prevalence of diabetes, which continues to rise due to factors such as urbanization, dietary changes, and sedentary lifestyles. As the healthcare infrastructure improves, there is greater access to insulin therapy, fostering market growth. Additionally, advancements in insulin formulations, including long-acting and rapid-acting varieties, enhance patient compliance and treatment outcomes, contributing to market expansion. The growing awareness and demand for affordable diabetes care options further propel the market. Moreover, government initiatives aimed at improving healthcare access and reducing the burden of diabetes support market growth. The rising focus on personalized medicine and the shift towards more cost-effective insulin solutions are also influencing trends in the sector. With continuous innovation and a larger diabetic population, the Mexico Human Insulin market is poised for steady growth throughout the forecast period.

The geographical landscape of the Mexico Human Insulin market is shaped by urban centers such as Mexico City, Monterrey, Guadalajara, and Tijuana, where the concentration of healthcare facilities and a higher prevalence of diabetes drive strong demand for insulin therapies. These cities benefit from better medical infrastructure, greater access to public and private healthcare services, and increased awareness of diabetes management. As a result, insulin manufacturers are focusing their distribution networks and outreach efforts on these high-density regions. In terms of key players, the market is dominated by major pharmaceutical companies such as Novo Nordisk A/S, Eli Lilly and Company, and Sanofi, which offer a wide range of insulin products including analogues and biosimilars. Other notable players include Pfizer, Biocon, Wockhardt, Lupin, and Tonghua Dongbao Pharmaceutical Co., who are strengthening their positions by expanding product portfolios, leveraging partnerships, and investing in research to deliver cost-effective and innovative diabetes care solutions in Mexico.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The Mexico Human Insulin market was valued at USD 536.37 million in 2023 and is projected to reach USD 706.76 million by 2032, growing at a CAGR of 3.10%.

The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.

Rising diabetes prevalence, particularly Type 2, is significantly increasing demand for insulin therapies across urban regions.
Insulin analogues are replacing traditional insulin due to improved efficacy and lower hypoglycemia risks.
Leading companies like Novo Nordisk, Eli Lilly, and Biocon dominate the competitive landscape with diversified insulin portfolios.
Regulatory complexities and cold chain logistics remain key challenges for consistent insulin supply in remote areas.
Mexico City holds the highest regional market share at over 35%, followed by Monterrey and Guadalajara.
Biosimilar insulin products are emerging as cost-effective alternatives, encouraging broader access and affordability.

Report Scope

This report segments the Mexico Human Insulin Market as follows:

Market Drivers

Rising Prevalence of Diabetes

The increasing prevalence of diabetes in Mexico is a significant driver of the Human Insulin market. For instance, Mexico had 13.6 million adults living with diabetes in 2024, making it one of the top ten countries globally with the highest number of diabetic patients. As urbanization accelerates and lifestyles change, there is a growing incidence of type 1 and type 2 diabetes, both of which require insulin for management. According to the International Diabetes Federation (IDF), diabetes is a major health concern in Mexico, with millions of people living with the condition. Factors such as poor dietary habits, sedentary lifestyles, and obesity contribute to the rising number of diabetes cases. As the disease burden grows, the demand for insulin therapy to regulate blood glucose levels has surged, driving the expansion of the insulin market in the region. The need for regular insulin injections among a larger diabetic population continues to push the growth of the market.

Enhanced Access to Healthcare Services

Improvements in healthcare infrastructure and the accessibility of medical treatments are essential drivers of market growth. For instance, Mexico has made significant strides in improving healthcare services, particularly in urban and semi-urban areas, with government-backed initiatives supporting better access to diabetes care. This has made it easier for diabetic patients to access essential medications, including insulin. The expansion of public and private healthcare facilities, coupled with government-backed initiatives to promote better access to healthcare, has contributed to the growth of the insulin market. Moreover, affordability and coverage of insulin therapies through public healthcare programs and private insurance plans have made insulin more accessible to a larger portion of the population, boosting market penetration.

Advancements in Insulin Formulations

Technological advancements in insulin formulations have also played a crucial role in driving the Mexico Human Insulin market. Modern insulin therapies, such as rapid-acting insulin and long-acting insulin, have improved the management of diabetes by providing patients with better flexibility and control over their blood glucose levels. These advancements address patient needs for more precise and individualized treatment options. Additionally, insulin pens and other user-friendly delivery devices have made insulin administration easier, contributing to increased patient adherence to prescribed therapies. As pharmaceutical companies continue to innovate and develop new insulin formulations, the market is witnessing a shift towards more efficient and effective treatment options. The rising demand for advanced insulin products further boosts market growth.

Growing Awareness and Government Initiatives

Increased awareness about diabetes management and government-led initiatives to combat the growing diabetes epidemic are key market drivers. As public health campaigns and educational programs continue to highlight the importance of early diabetes diagnosis and proper management, more individuals are seeking treatment for diabetes, including insulin therapy. Mexico’s government has been proactive in addressing the diabetes crisis through programs aimed at providing better access to healthcare services, increasing the availability of insulin, and promoting lifestyle changes to prevent and manage diabetes. These efforts, coupled with the rising awareness of diabetes complications, have spurred demand for human insulin. As a result, government support and initiatives play a vital role in fostering market growth and expanding the reach of insulin therapies across the population.

Market Trends

Shift Towards Insulin Analogues

The Mexico Human Insulin market is witnessing a significant shift towards insulin analogues, which offer superior control over blood glucose levels compared to traditional human insulin. For instance, insulin analogues such as rapid-acting, long-acting, and ultra-long-acting formulations are increasingly preferred due to their ability to provide more consistent and predictable blood glucose regulation. Insulin analogues, such as rapid-acting, long-acting, and ultra-long-acting formulations, provide more consistent and predictable blood glucose regulation, reducing the risk of hypoglycemia. This shift is driven by the growing preference for more effective and patient-friendly diabetes management options. For instance, insulin analogues allow for better flexibility in meal timing and improve overall glycemic control, making them a preferred choice among healthcare providers. As diabetes care becomes more personalized, insulin analogues are increasingly integrated into treatment regimens due to their ability to better meet individual patient needs. With their higher efficacy and patient convenience, insulin analogues are expected to dominate the market, leading to a substantial increase in their adoption and use across Mexico in the coming years.

Regulatory and Supply Chain Challenges

Despite the positive trends, the Mexico Human Insulin market faces several challenges related to regulatory requirements and supply chain disruptions. For instance, the regulatory environment in Mexico is complex, with stringent guidelines and approval processes for pharmaceutical products, including insulin. These regulations are necessary to ensure patient safety and the efficacy of insulin products, but they can also delay the market entry of new insulin formulations and biosimilar products. Additionally, the need for temperature-controlled storage and transportation of insulin poses logistical challenges, particularly in rural or remote regions of Mexico. Any disruption in the supply chain, such as production delays or distribution challenges, can impact the availability of insulin, leading to potential shortages and increased costs. As the market grows, addressing these regulatory and supply chain challenges will be crucial for ensuring a steady and consistent supply of insulin therapies to meet the rising demand. Efficient management of these challenges will be essential to the sustainable growth of the Mexico Human Insulin market.

Adoption of Insulin Pens

The growing adoption of insulin pens is another key trend shaping the Mexico Human Insulin market. Insulin pens, which offer a more convenient and precise way of administering insulin, are gaining popularity among both patients and healthcare professionals. Unlike traditional vials and syringes, insulin pens are portable, easy to use, and require fewer steps to administer insulin. They offer patients better dose accuracy, reducing the risk of dosing errors. In addition, disposable insulin pens offer a hygienic and convenient option for individuals who may face difficulty with manual injections. With their user-friendly design, insulin pens are particularly beneficial for patients who require insulin multiple times a day. This trend towards insulin pen usage is expected to continue rising, as it improves patient compliance and overall satisfaction with diabetes management.

Emergence of Biosimilar Insulin Products

The introduction of biosimilar insulin products represents a transformative trend in the Mexico Human Insulin market, as these products provide a cost-effective alternative to brand-name insulin. Biosimilars are highly similar to the original branded insulins, with comparable safety, efficacy, and quality. The availability of biosimilars can reduce treatment costs, making insulin therapy more accessible to a larger segment of the population, particularly in regions with limited healthcare budgets. The Mexican government has already begun to encourage the use of biosimilars as part of its efforts to reduce healthcare expenditures and improve accessibility. Several biosimilar insulin products have already entered the market, and their adoption is expected to increase as more regulatory approvals are granted. The entry of biosimilars into the market will foster greater competition, driving down prices and improving the affordability of insulin for Mexican patients. This trend is likely to have a significant impact on the overall dynamics of the market, enabling more people to access the life-saving medication they need to manage diabetes.

Market Challenges Analysis

Regulatory Hurdles and Delays

One of the primary challenges facing the Mexico Human Insulin market is navigating the stringent regulatory environment. For instance, the approval process for insulin products in Mexico requires compliance with a complex set of regulatory standards set by the Federal Commission for the Protection against Sanitary Risk (COFEPRIS). These regulations are necessary to ensure the safety and efficacy of diabetes treatments, but they can also lead to significant delays in the market introduction of new insulin formulations and biosimilar products. The lengthy approval timelines can hinder the rapid availability of innovative insulin therapies that could benefit patients. Additionally, any changes or updates to regulatory guidelines can introduce uncertainty, slowing down the adoption of new technologies and making it more difficult for manufacturers to predict market entry. These regulatory hurdles can ultimately impact the ability to meet the increasing demand for insulin therapies, limiting market growth potential.

Supply Chain and Accessibility Issues

The Mexico Human Insulin market also faces significant supply chain challenges that can affect the consistent availability and distribution of insulin products. Insulin requires strict temperature control during storage and transportation to maintain its efficacy, which can complicate logistics, particularly in rural and underserved areas of the country. Disruptions in the supply chain—whether due to manufacturing delays, transportation issues, or regulatory bottlenecks—can lead to insulin shortages, making it difficult for patients to access their necessary treatments. Furthermore, the reliance on both public and private healthcare systems to distribute insulin can create disparities in access, especially for lower-income populations. The high cost of insulin, compounded by logistical issues, also contributes to accessibility concerns, as patients may be unable to afford or obtain the medication they need. Overcoming these supply chain barriers will be essential for ensuring that insulin remains accessible to all diabetic patients in Mexico.

Market Opportunities

The Mexico Human Insulin market presents significant growth opportunities driven by several factors. As the prevalence of diabetes continues to rise, the demand for insulin therapies is expected to increase steadily. With a growing diabetic population, particularly in urban areas, there is an expanding need for innovative and affordable insulin solutions. This trend creates opportunities for both global and local insulin manufacturers to introduce new formulations, including rapid-acting, long-acting, and biosimilar insulins, to meet the diverse needs of patients. Additionally, as healthcare infrastructure improves and more people gain access to healthcare services, the market is well-positioned to benefit from greater demand for insulin therapies, especially as government initiatives aim to improve diabetes care and access to essential medications. Manufacturers can capitalize on this growing demand by focusing on product innovation and expanding their distribution networks to reach underserved regions.

Furthermore, the shift towards biosimilar insulins presents a notable market opportunity. As healthcare systems worldwide look to reduce costs, the affordability of biosimilar insulin products makes them an attractive option for both patients and healthcare providers. The regulatory landscape in Mexico is evolving to support the introduction of biosimilars, which could foster greater competition and lower prices, ultimately expanding patient access to insulin. This is especially important in a country where the cost of branded insulin can be a barrier to treatment for many individuals. By tapping into this segment of the market, insulin manufacturers can provide more cost-effective solutions while benefiting from the growing demand for affordable diabetes management options. Overall, the Mexico Human Insulin market holds promising opportunities for growth, driven by increasing diabetes cases, improved healthcare access, and the adoption of cost-effective insulin alternatives.

Market Segmentation Analysis:

By Device:

The Mexico Human Insulin market is divided into several segments based on the type of delivery device used. The most prominent segments are insulin pens, syringes, and other delivery methods. Insulin pens are experiencing significant growth due to their convenience, accuracy, and ease of use. These pens offer more precise insulin doses, which improve patient compliance, and their portable design makes them popular among both patients and healthcare providers. The increasing adoption of insulin pens is evident in the growing demand, especially for pre-filled and reusable pens, which contribute to patient satisfaction and convenience. On the other hand, insulin syringes, while still widely used, are seeing a slower growth rate due to the rising preference for pens. They remain an affordable option for many patients but are less favored due to the less accurate dosing and more cumbersome injection process. Additionally, other delivery methods such as insulin pumps and jet injectors cater to a niche market, offering alternative delivery options for patients who require more advanced or customized insulin regimens. As the market continues to evolve, insulin pens are expected to dominate the device segment, driven by ongoing advancements in design and patient-centric features.

By Indication:

The Mexico Human Insulin market is also segmented based on the indication for which insulin is prescribed, which includes Type 1 diabetes, Type 2 diabetes, and gestational diabetes. Type 1 diabetes remains a key driver of insulin demand, as individuals with this condition require lifelong insulin therapy for glucose regulation. The market for Type 1 diabetes is expected to continue growing due to the increasing diagnosis of the condition and better access to healthcare services. Type 2 diabetes, which is more prevalent and closely linked to lifestyle factors such as obesity, sedentary living, and poor diet, represents a larger market segment. This segment is growing rapidly due to the rising incidence of Type 2 diabetes, particularly in urban areas. Insulin is prescribed to manage blood glucose levels in patients whose condition cannot be controlled by oral medications alone. Gestational diabetes, a temporary condition that occurs during pregnancy, is another important segment. Though less common, the demand for insulin during pregnancy is rising, especially as awareness of the condition increases. As healthcare awareness improves, these three key segments: Type 1, Type 2, and gestational diabetes—will continue to drive the demand for insulin therapies across Mexico.

Segments:

Based on Device:

Pens
Syringes
Others

Based on Indication:

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Based on Insulin:

Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others

Based on Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

Based on the Geography:

Mexico City
Monterrey
Guadalajara
Tijuana

Regional Analysis

Mexico City

Mexico City held the largest share of the market, contributing to over 35% of the total market. As the capital and the most populous city in Mexico, Mexico City has the highest concentration of healthcare facilities, including hospitals, clinics, and specialized diabetes care centers. The city’s robust healthcare infrastructure and access to advanced insulin therapies have led to a higher demand for insulin products, particularly among the growing diabetic population. Additionally, Mexico City benefits from greater awareness of diabetes management and more widespread access to healthcare services, further solidifying its position as the largest market for human insulin in Mexico.

Monterrey

Monterrey, the capital of Nuevo León and one of Mexico’s largest metropolitan areas, follows closely in market share with approximately 25%. Known for its industrial growth and economic significance, Monterrey has a well-developed healthcare sector that caters to a large urban population. The region is home to a significant number of private and public healthcare institutions that provide comprehensive diabetes management services, increasing demand for insulin products. The rising prevalence of Type 2 diabetes in Monterrey, driven by lifestyle factors such as diet and sedentary behavior, is further fueling the market for insulin. With a strong healthcare infrastructure and a high concentration of the population living in urban areas, Monterrey plays a vital role in the growth of the Mexico Human Insulin market.

Guadalajara

Guadalajara, located in the western part of Mexico, accounts for approximately 20% of the total market share. As the second-largest city in the country, Guadalajara has a growing population and a rapidly expanding healthcare sector. The city is known for its well-established public health systems and increasing private healthcare facilities, which are crucial for the distribution of insulin therapies. Guadalajara’s role as a major medical hub has positioned it as a key market for human insulin, particularly as awareness of diabetes management continues to grow. Additionally, the region benefits from an increasing number of diabetes patients who require insulin as part of their treatment regimen, contributing to the expanding demand for insulin products.

Tijuana

Tijuana, located along the U.S.-Mexico border, accounts for around 10% of the Mexico Human Insulin market share. While it holds a smaller market share compared to the larger cities, Tijuana is significant due to its proximity to the United States, which has led to an influx of cross-border healthcare services. Many patients in Tijuana have access to both Mexican and American healthcare systems, providing a unique opportunity for insulin manufacturers to reach a broader audience. The market is also influenced by the increasing number of people diagnosed with diabetes, both in Mexico and from neighboring regions, further driving the demand for insulin. Despite its smaller share, Tijuana continues to play an important role in the distribution of human insulin, driven by its cross-border healthcare dynamics and growing diabetic population.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Tonghua Dongbao Pharmaceutical Co
Eli Lilly and Company

Competitive Analysis

The competitive landscape of the Mexico Human Insulin market is characterized by the presence of several global and regional pharmaceutical companies striving to strengthen their positions through innovation, strategic collaborations, and affordability. Leading players such as Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Pfizer, Biocon, Wockhardt, Lupin, MannKind Corporation, and Tonghua Dongbao Pharmaceutical Co. play a pivotal role in shaping the market dynamics. These companies offer a comprehensive range of insulin formulations, including rapid-acting, long-acting, and biosimilar insulins, catering to diverse patient needs. Competitive strategies such as product innovation, investments in research and development, and strategic partnerships with local distributors are commonly employed to strengthen market presence. In addition, companies are prioritizing accessibility by introducing cost-effective insulin options and expanding their outreach into underserved regions. Regulatory compliance and the ability to maintain consistent product quality also contribute to a company’s competitive standing in the market. As biosimilar insulin gains traction, pricing pressure is increasing, leading to intensified competition among manufacturers. The focus on patient-centric care, coupled with advanced delivery devices such as insulin pens, is further driving competition and shaping the future of the market.

Recent Developments

In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.

Market Concentration & Characteristics

The Mexico Human Insulin market exhibits a moderately high level of market concentration, characterized by the dominance of a few well-established multinational pharmaceutical companies that possess strong brand portfolios, advanced manufacturing capabilities, and widespread distribution networks. These players maintain a significant share of the market by offering a broad range of insulin products, including traditional human insulin and newer insulin analogues. The market is further shaped by the increasing presence of biosimilar insulin manufacturers aiming to provide cost-effective alternatives. Key characteristics of the market include a strong demand for innovative delivery devices such as insulin pens, growing adoption of biosimilars, and a rising focus on patient-centric diabetes care. While innovation and affordability remain critical factors, regulatory compliance and logistical efficiency also play a vital role in maintaining competitiveness. As the market continues to evolve, its concentration will likely remain influenced by technological advancements, pricing strategies, and efforts to improve accessibility across urban and underserved regions.

Report Coverage

The research report offers an in-depth analysis based on Device, Indication, Insulin, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The demand for insulin in Mexico is expected to grow steadily due to the increasing prevalence of diabetes.
Biosimilar insulin products will gain greater market traction as affordability becomes a key priority.
Advanced insulin delivery devices such as smart pens and pumps will see wider adoption.
Public health initiatives will likely expand access to insulin in underserved and rural areas.
Local manufacturing and partnerships may increase to reduce dependency on imports.
Digital health tools will support diabetes management and improve patient adherence to insulin therapy.
Regulatory frameworks will continue evolving to accommodate new insulin formulations and biosimilars.
Urban centers will remain primary markets, but regional outreach will become a strategic focus.
Companies will invest more in research to develop long-acting and ultra-fast insulin variants.
Patient education programs will play a crucial role in boosting awareness and improving outcomes.

CHAPTER NO. 1 : INTRODUCTION 19

1.1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.1.2. Key Benefits for Stakeholders 19

1.1.3. Target Audience 20

1.1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. Human Insulin Market Snapshot 21

2.1.1. Mexico Human Insulin Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23

3.1. Russia-Ukraine and Israel-Palestine War Impacts 23

CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 24

4.1. Introduction 24

4.2. Market Drivers 25

4.2.1. Driving Factor 1 Analysis 25

4.2.2. Driving Factor 2 Analysis 26

4.3. Market Restraints 27

4.3.1. Restraining Factor Analysis 27

4.4. Market Opportunities 28

4.4.1. Market Opportunity Analysis 28

4.5. Porter’s Five Forces Analysis 29

4.6. Value Chain Analysis 30

4.7. Buying Criteria 31

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32

5.1. Import Analysis by Mexico 32

5.1.1. Mexico Human Insulin Market Import Volume/Revenue, By Mexico, 2018 – 2023 32

5.2. Export Analysis by Mexico 33

5.2.1. Mexico Human Insulin Market Export Volume/Revenue, By Mexico, 2018 – 2023 33

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34

6.1. Demand Analysis by Mexico 34

6.1.1. Mexico Human Insulin Market Demand Volume/Revenue, By Mexico, 2018 – 2023 34

6.2. Supply Analysis by Mexico 35

6.2.1. Mexico Human Insulin Market Supply Volume/Revenue, By Mexico, 2018 – 2023 35

CHAPTER NO. 7 : PRODUCTION ANALYSIS 36

7.1. Production Analysis by Mexico 36

7.1.1. Mexico Human Insulin Market Production Volume/Revenue, By Mexico, 2018 – 2023 36

CHAPTER NO. 8 : PRICE ANALYSIS 37

8.1. Price Analysis by Type 37

8.1.1. Mexico Human Insulin Market Price, By Type, 2018 – 2023 37

8.1.2. Mexico Type Market Price, By Type, 2018 – 2023 37

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38

9.1. Key Raw Materials and Suppliers 38

9.2. Key Raw Materials Price Trend 38

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39

10.1. Manufacturing Cost Analysis 39

10.2. Manufacturing Process 39

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40

11.1. Company Market Share Analysis – 2023 40

11.1.1. Mexico Human Insulin Market: Company Market Share, by Volume, 2023 40

11.1.2. Mexico Human Insulin Market: Company Market Share, by Revenue, 2023 41

11.1.3. Mexico Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 41

11.1.4. Mexico Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 42

11.2. Mexico Human Insulin Market Company Volume Market Share, 2023 43

11.3. Mexico Human Insulin Market Company Revenue Market Share, 2023 44

11.4. Company Assessment Metrics, 2023 45

11.4.1. Stars 45

11.4.2. Emerging Leaders 45

11.4.3. Pervasive Players 45

11.4.4. Participants 45

11.5. Start-ups /SMEs Assessment Metrics, 2023 45

11.5.1. Progressive Companies 45

11.5.2. Responsive Companies 45

11.5.3. Dynamic Companies 45

11.5.4. Starting Blocks 45

11.6. Strategic Developments 46

11.6.1. Acquisitions & Mergers 46

New Product Launch 46

Mexico Expansion 46

11.7. Key Players Product Matrix 47

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48

12.1. PESTEL 48

12.1.1. Political Factors 48

12.1.2. Economic Factors 48

12.1.3. Social Factors 48

12.1.4. Technological Factors 48

12.1.5. Environmental Factors 48

12.1.6. Legal Factors 48

12.2. Adjacent Market Analysis 48

CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY TYPE SEGMENT ANALYSIS 49

13.1. Human Insulin Market Overview, by Type Segment 49

13.1.1. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

13.1.2. Human Insulin Market Attractiveness Analysis, By Type 51

13.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 51

13.1.4. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

13.2. Pens 53

13.3. Syringes 54

13.4. Others 55

13.5. Type 4 56

13.6. Type 5 57

CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY APPLICATION SEGMENT ANALYSIS 58

14.1. Human Insulin Market Overview, by Application Segment 58

14.1.1. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

14.1.2. Human Insulin Market Attractiveness Analysis, By Application 60

14.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 60

14.1.4. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

14.2. Type 1 Diabetes 62

14.3. Type 2 Diabetes 63

14.4. Gestational Diabetes 64

14.5. Application 4 65

14.6. Application 5 66

CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY END-USER SEGMENT ANALYSIS 67

15.1. Human Insulin Market Overview, by End-user Segment 67

15.1.1. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

15.1.2. Human Insulin Market Attractiveness Analysis, By End-user 69

15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 69

15.1.4. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

15.2. Rapid-acting insulin 71

15.3. Short-acting insulin 72

15.4. Intermediate-acting insulin 73

15.5. Others 74

15.6. End-user 5 75

CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76

16.1. Human Insulin Market Overview, by Technology Segment 76

16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 78

16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78

16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

16.2. Technology 1 80

16.3. Technology 2 81

16.4. Technology 3 82

CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83

17.1. Human Insulin Market Overview, by Distribution Channel Segment 83

17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 85

17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85

17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

17.2. Hospital Pharmacies 87

17.3. Drug Stores and Retail Pharmacies 88

17.4. Online Providers 89

17.5. Distribution Channel 4 90

17.6. Distribution Channel 5 91

CHAPTER NO. 18 : HUMAN INSULIN MARKET – MEXICO ANALYSIS 92

18.1. Type 92

18.1.1. Mexico Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 92

18.2. Mexico Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 92

18.3. Application 93

18.3.1. Mexico Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 93

18.3.2. Mexico Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 93

18.4. End-user 94

18.4.1. Mexico Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

18.4.2. Mexico Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 94

18.5. Technology 95

18.5.1. Mexico Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 95

18.5.2. Mexico Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 95

18.6. Distribution Channel 96

18.6.1. Mexico Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96

18.6.2. Mexico Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96

CHAPTER NO. 19 : COMPANY PROFILES 97

19.1. Novo Nordisk A/S 97

19.1.1. Company Overview 97

19.1.2. Product Portfolio 97

19.1.3. Swot Analysis 97

19.1.4. Business Strategy 98

19.1.5. Financial Overview 98

19.1.6. MannKind Corporation 99

19.1.7. Pfizer 99

19.1.8. Wockhardt 99

19.1.9. Biocon 99

19.1.10. Lupin 99

19.1.11. Tonghua Dongbao Pharmaceutical Co 99

19.1.12. Eli Lilly and Company 99

19.1.13. Company 9 99

19.1.14. Company 10 99

19.1.15. Company 11 99

19.1.16. Company 12 99

19.1.17. Company 13 99

19.1.18. Company 14 99

CHAPTER NO. 20 : RESEARCH METHODOLOGY 100

20.1. Research Methodology 100

20.1.1. Phase I – Secondary Research 101

20.1.2. Phase II – Data Modeling 101

Company Share Analysis Model 102

Revenue Based Modeling 102

20.1.3. Phase III – Primary Research 103

20.1.4. Research Limitations 104

Assumptions 104

List of Figures

FIG NO. 1. Mexico Human Insulin Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for Mexico Human Insulin Market 29

FIG NO. 3. Value Chain Analysis for Mexico Human Insulin Market 30

FIG NO. 4. Mexico Human Insulin Market Import Volume/Revenue, By Mexico, 2018 – 2023 32

FIG NO. 5. Mexico Human Insulin Market Export Volume/Revenue, By Mexico, 2018 – 2023 33

FIG NO. 6. Mexico Human Insulin Market Demand Volume/Revenue, By Mexico, 2018 – 2023 34

FIG NO. 7. Mexico Human Insulin Market Supply Volume/Revenue, By Mexico, 2018 – 2023 35

FIG NO. 8. Mexico Human Insulin Market Production Volume/Revenue, By Mexico, 2018 – 2023 36

FIG NO. 9. Mexico Human Insulin Market Price, By Type, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. Human Insulin Market – Company Volume Market Share, 2023 43

FIG NO. 18. Human Insulin Market – Company Revenue Market Share, 2023 44

FIG NO. 19. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Type 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 51

FIG NO. 22. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

FIG NO. 23. Mexico Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. Mexico Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. Mexico Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. Mexico Human Insulin Market for Type 4, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. Mexico Human Insulin Market for Type 5, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Application 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 60

FIG NO. 31. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

FIG NO. 32. Mexico Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. Mexico Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. Mexico Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. Mexico Human Insulin Market for Application 4, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. Mexico Human Insulin Market for Application 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By End-user 69

FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69

FIG NO. 40. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

FIG NO. 41. Mexico Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. Mexico Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. Mexico Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. Mexico Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. Mexico Human Insulin Market for End-user 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By Technology 78

FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78

FIG NO. 49. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

FIG NO. 50. Mexico Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. Mexico Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. Mexico Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85

FIG NO. 56. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. Mexico Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. Mexico Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. Mexico Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. Mexico Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. Mexico Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

List of Tables

TABLE NO. 1. : Mexico Human Insulin Market: Snapshot 18

TABLE NO. 2. : Drivers for the Human Insulin Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the Human Insulin Market: Impact Analysis 24

TABLE NO. 4. : Mexico Human Insulin Market Revenue, By Type, 2018 – 2023 34

TABLE NO. 5. : Key Raw Materials & Suppliers 35

TABLE NO. 6. : Mexico Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 89

TABLE NO. 7. : Mexico Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 89

TABLE NO. 8. : Mexico Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 90

TABLE NO. 9. : Mexico Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 90

TABLE NO. 10. : Mexico Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 91

TABLE NO. 11. : Mexico Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 91

TABLE NO. 12. : Mexico Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 92

TABLE NO. 13. : Mexico Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 92

TABLE NO. 14. : Mexico Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93

TABLE NO. 15. : Mexico Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93

Frequently Asked Questions

What is the current size of the Mexico Human Insulin?

The market was valued at USD 536.37 million in 2023 and is projected to reach USD 706.76 million by 2032.

What factors are driving the growth of the Mexico Human Insulin?

Rising diabetes prevalence, improved healthcare access, insulin analogues, biosimilars, and government initiatives are key drivers.

What are some challenges faced by the Mexico Human Insulin?

Challenges include regulatory hurdles, cold chain logistics, and limited insulin access in rural areas.

Who are the major players in the Mexico Human Insulin?

Major players include Novo Nordisk, Eli Lilly, Sanofi, Pfizer, Biocon, Wockhardt, MannKind, and Tonghua Dongbao.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$8699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –